HomeAbout

TL;DR CNBC


FDA staff report says data shows Pfizer's Covid treatment Paxlovid is effective in high-risk adults - TL;DR CNBC

FDA staff report says data shows Pfizer's Covid treatment Paxlovid is effective in high-risk adults

Publishing timestamp: 2023-03-14 17:23:53


Summary

FDA staff have concluded that Pfizer's clinical trial results on its Covid antiviral pill Paxlovid support the drug's use in adults at high risk of progressing to severe disease. The external advisors on the agency's Antimicrobial Drugs Advisory Committee will discuss whether to recommend full approval of Paxlovid for treatment of mild to moderate Covid in high-risk adults. The meeting comes as companies like Pfizer brace for a drop in sales of Covid vaccines and treatments that led to record revenues earlier in the pandemic. Sales of Paxlovid jumped to $18.9 billion in 2022, but the company expects that revenue to drop 58% to $8 billion this year.


Sentiment: NEUTRAL

Tickers: MRNAPFE

Keywords: pfizer inchealth care industrybusiness newsbiotechnologyunited statespharmaceuticalsmoderna incbreaking news: businessbreaking newsbiotech and pharmaceuticals

Source: https://www.cnbc.com/2023/03/14/fda-staff-report-says-data-shows-pfizers-covid-treatment-paxlovid-is-effective-in-high-risk-adults.html


Developed by Leo Phan